Home
/
TG THERAPEUTICS, INC.
/
Financials
/
Quarterly
TG THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that TG THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Sep 30, 2022
$94.0K
Nov 9, 2022
Q2
2022
Jun 30, 2022
$594.0K
Aug 9, 2022
Q1
2022
Mar 31, 2022
$2.02M
May 10, 2022
Q3
2022
Sep 30, 2021
$2.03M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$1.55M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$793.0K
May 10, 2022
Q3
2021
Sep 30, 2020
$38.0K
Nov 8, 2021
Q2
2021
Jun 30, 2020
$38.0K
Aug 6, 2021
Q1
2021
Mar 31, 2020
$38.0K
May 10, 2021
Q3
2020
Sep 30, 2019
$38.0K
Nov 9, 2020
Q2
2020
Jun 30, 2019
$38.0K
Aug 10, 2020
Q1
2020
Mar 31, 2019
$38.0K
May 11, 2020
Q3
2019
Sep 30, 2018
$38.0K
Nov 12, 2019
Q2
2019
Jun 30, 2018
$38.0K
Aug 9, 2019
Q1
2019
Mar 31, 2018
$38.0K
May 10, 2019
Q3
2018
Sep 30, 2017
$38.0K
Nov 9, 2018
Q2
2018
Jun 30, 2017
$38.0K
Aug 9, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$161.71M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$141.15M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$120.86M
May 9, 2025
Q3
2025
Sep 30, 2024
$83.88M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$73.47M
Aug 8, 2025
Q1
2025
Mar 31, 2024
$63.47M
May 9, 2025
Q3
2024
Sep 30, 2023
$165.82M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$16.07M
Aug 9, 2024
Q1
2024
Mar 31, 2023
$7.80M
May 6, 2024
Q3
2023
Sep 30, 2022
$94.0K
Nov 6, 2023
Q2
2023
Jun 30, 2022
$594.0K
Aug 4, 2023
Q1
2023
Mar 31, 2022
$2.02M
May 8, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$390.90M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$28.19M
Aug 8, 2025
Q3
2025
Jun 30, 2025
$28.19M
Nov 5, 2025
Q3
2025
Mar 31, 2025
$5.06M
Nov 5, 2025
Q2
2025
Mar 31, 2025
$5.06M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$5.06M
May 9, 2025
Q3
2025
Sep 30, 2024
$3.88M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$6.88M
Aug 8, 2025
Q3
2025
Jun 30, 2024
$6.88M
Nov 5, 2025
Q3
2025
Mar 31, 2024
($10.71M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($10.71M)
May 9, 2025
Q2
2025
Mar 31, 2024
($10.71M)
Aug 8, 2025
Q3
2024
Sep 30, 2023
$113.93M
Nov 7, 2024
Q3
2024
Jun 30, 2023
($47.61M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($47.61M)
Aug 9, 2024
Q2
2024
Mar 31, 2023
($39.23M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($39.23M)
May 6, 2024
Q3
2024
Mar 31, 2023
($39.23M)
Nov 7, 2024
Q3
2023
Sep 30, 2022
($35.82M)
Nov 6, 2023
Q3
2023
Jun 30, 2022
($40.51M)
Nov 6, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$29.37M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$34.84M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$8.62M
May 9, 2025
Q3
2025
Sep 30, 2024
$12.43M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$8.82M
Aug 8, 2025
Q1
2025
Mar 31, 2024
($9.27M)
May 9, 2025
Q3
2024
Sep 30, 2023
$114.78M
Nov 7, 2024
Q2
2024
Jun 30, 2023
($44.67M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($36.99M)
May 6, 2024
Q3
2023
Sep 30, 2022
($34.96M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($38.94M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
($66.87M)
May 8, 2023
Q3
2022
Sep 30, 2021
($85.13M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($77.49M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($89.20M)
May 10, 2022
Q3
2021
Sep 30, 2020
($85.72M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($50.85M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
($50.25M)
May 10, 2021
Q3
2020
Sep 30, 2019
($60.86M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($35.54M)
Aug 10, 2020